SOLU-MEDROL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SOLU-MEDROL (SOLU-MEDROL).
Corticosteroid with anti-inflammatory and immunosuppressive properties; suppresses inflammatory cytokines and immune cell activity.
| Metabolism | Hepatic metabolism via CYP3A4 |
| Excretion | Renal: approximately 80% as metabolites (glucuronide and sulfate conjugates) and unchanged drug; biliary/fecal: less than 5%. |
| Half-life | Terminal elimination half-life: 2.5–3.5 hours. In clinical context, the biologic half-life (suppression of HPA axis) is longer (24–36 hours) due to tissue retention of active metabolites. |
| Protein binding | Approximately 77% bound to corticosteroid-binding globulin (CBG) and albumin; binding is concentration-dependent. |
| Volume of Distribution | Vd: 0.8–1.0 L/kg. Indicates extensive tissue distribution, including penetration into cerebrospinal fluid. |
| Bioavailability | Intravenous: 100%; intramuscular: approximately 80–100% (highly variable due to injection conditions). Oral methylprednisolone (not Solu-Medrol itself) has bioavailability of 70–80%. |
| Onset of Action | Intravenous: within minutes (peak effect at 15–30 minutes); intramuscular: 1–2 hours; oral (not a typical route for Solu-Medrol, but methylprednisolone tablets): 1–2 hours. |
| Duration of Action | Duration of HPA axis suppression: 24–36 hours following a single dose. Clinical duration of anti-inflammatory effect may persist for 48–72 hours. |
| Molecular Weight | 416.51 |
| Action Class | Glucocorticoids |
| Brand Substitutes | Deposet 40mg Injection, Mepsonate 40mg Injection, Mypred 40mg Injection, Mepresso D 40mg Injection, Neo-Drol 40mg Injection, Celopred 500mg Injection, Mepresso 500mg Injection, Premisol 500mg Injection, Sol U Pred 500mg Injection, Methymic 500 Injection, Sanipred 125mg Injection, Predzen 125mg Injection, Elopred 125mg Injection, Succimed 125mg Injection, Premisol 125mg Injection, Lepred 250mg Injection, Desone 250mg Injection, Solu Medrol 250mg Injection |
IV or IM: 10-40 mg methylprednisolone (as sodium succinate) every 4-6 hours; high-dose pulse therapy: 30 mg/kg IV over 30-60 minutes every 4-6 hours for 48-72 hours.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment required for renal impairment; hemodialysis does not significantly remove methylprednisolone. |
| Liver impairment | Severe hepatic impairment (Child-Pugh class C): reduce dose by 50% or consider alternative; monitor for enhanced effects. |
| Pediatric use | IV/IM: 0.5-1.7 mg/kg/day in divided doses every 6-12 hours; pulse therapy: 30 mg/kg IV every 4-6 hours for 48-72 hours. |
| Geriatric use | Use lowest effective dose; monitor for hyperglycemia, osteoporosis, and fluid retention; consider reduced initial dose due to increased sensitivity. |
| 1st trimester | Corticosteroids are associated with increased risk of cleft palate (1-2/1000 births) when used in first trimester. Use only if clearly needed. |
| 2nd trimester | May cause fetal growth retardation and adrenal suppression if used chronically. Short-term use for maternal benefit is considered acceptable. |
| 3rd trimester | Prolonged use may lead to neonatal adrenal suppression. Short courses for fetal lung maturation are standard of care (e.g., betamethasone preferred). |
Clinical note
Comprehensive clinical and safety monograph for SOLU-MEDROL (SOLU-MEDROL).
| Placental transfer | Methylprednisolone crosses the placenta but is extensively metabolized; approximately 10-40% of maternal dose reaches fetus. Transplacental transfer is lower than with dexamethasone. |
| Breastfeeding | Methylprednisolone is excreted into breast milk in low concentrations. Doses up to 40 mg/day are generally considered compatible with breastfeeding. Monitor infant for potential growth suppression or adrenal suppression if high doses used. |
■ FDA Black Box Warning
None (no FDA boxed warning).
| Serious Effects |
Systemic fungal infectionsLive or live attenuated vaccine administration (except as therapy for certain conditions)Hypersensitivity to methylprednisolone or any component of the formulation
| Precautions | Immunosuppression and increased risk of infections, Adrenal suppression with prolonged use, Cushing's syndrome with prolonged use, Osteoporosis, Gastrointestinal perforation, Psychiatric disturbances, Ocular effects (cataracts, glaucoma), Growth suppression in children, Fluid and electrolyte disturbances |
| Food/Dietary | Grapefruit juice may increase systemic exposure; avoid concurrent use. Limit sodium intake due to fluid retention risk. Increase potassium-rich foods (bananas, spinach) if hypokalemia develops. Avoid alcohol. |
Loading safety data…
| Lactation Rating | L2 (Safer, limited data) |
| Teratogenic Risk | Pregnancy Category C. First trimester: Increased risk of oral clefts (odds ratio 1.3-3.4) based on epidemiological studies. Second/third trimester: Fetal adrenal suppression, growth restriction, and premature rupture of membranes with chronic high-dose use. No adequate controlled studies; use only if benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, and signs of infection. For prolonged use: fetal growth ultrasound every 4-6 weeks, and monitor for adrenal insufficiency in the neonate (hypoglycemia, hypotension). Consider non-stress test or biophysical profile in third trimester if indicated. |
| Fertility Effects | High doses may suppress endogenous gonadotropins, potentially causing menstrual irregularities or anovulation. Reversible upon dose reduction or discontinuation. Data limited; no known permanent impact on fertility. |
| Clinical Pearls | SOLU-MEDROL (methylprednisolone sodium succinate) is a high-potency corticosteroid for IV/IM use. Rapid onset within 1 hour. Use low-dose for acute exacerbations of MS (pulse therapy: 1 g/day IV for 3-5 days). Taper to avoid adrenal crisis. Monitor for hyperglycemia, hypokalemia, and infection. Do not administer intrathecally (contains benzyl alcohol). |
| Patient Advice | Do not stop this medication abruptly; dose must be tapered under doctor's supervision. · Inform your doctor if you have high blood pressure, diabetes, or a history of infections. · Avoid live vaccines while on this medication. · Report any signs of infection (fever, sore throat) or unusual bruising/bleeding. · Take with food to reduce stomach upset. |